Tags

Type your tag names separated by a space and hit enter

[Comparison of clinical efficacy between HLA-mismatched related and HLA-matched unrelated donor hematopoietic stem cell transplantation for hematopoietic malignancies].
Zhonghua Xue Ye Xue Za Zhi. 2014 Sep; 35(9):826-30.ZX

Abstract

OBJECTIVE

To compare the clinical efficacy of HLA- mismatched related donor (MRD) and HLA-matched unrelated donor (MUD) hematopoietic stem cell transplantation (HSCT) for hematopoietic malignancies.

METHODS

174 patients with hematopoietic malignancies undergoing allogeneic HSCT (allo-HSCT) (82 from MRD and 92 from MUD) between June 2002 and December 2012 were enrolled in this retrospective study. Hematopoietic engraftment, graft versus host disease (GVHD), relapse, overall survival (OS) and disease-free survival (DFS) were compared between MRD and MUD group.

RESULTS

There was no significant difference between MRD and MUD group in terms of age, gender, disease type and disease status before transplantation (all P>0.05). The incidence of Ⅰ-IV acute GVHD (aGVHD) was 62.2% and 54.3% in MRD and MUD group (P=0.295); the incidence of III-IV aGVHD between the two groups was 15.9% and 9.8% (P=0.229). The incidence of chronic GVHD (cGVHD) was 28.4% and 45.1% in MRD and MUD group (P=0.036), but there was no significant difference in the incidence of extensive cGVHD between the two groups (9.0% vs 12.2%, P=0.525). The mortality of GVHD was 8.5% and 10.9% in MRD and MUD group (P=0.605). The 10-year OS and DFS were (50.1±6.1)% and (48.8±6.1)% in MRD group, compared with (50.5±6.7)% and (46.3±6.2)% in MUD group (P=0.501, P=0.873, respectively). The 10-year cumulative relapse rate was (21.5±5.7)% and (37.6±7.3)% in MRD and MUD group (P=0.194).

CONCLUSION

MRD is equivalent to MUD in efficacy and safety. Without HLA- matched related donors, MRD is superior to MUD because donor source is unlimited and transplantation could be made promptly according to disease status.

Authors+Show Affiliations

Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.

Pub Type(s)

Comparative Study
Journal Article

Language

chi

PubMed ID

25246252

Citation

Yu, Sijian, et al. "[Comparison of Clinical Efficacy Between HLA-mismatched Related and HLA-matched Unrelated Donor Hematopoietic Stem Cell Transplantation for Hematopoietic Malignancies]." Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi, vol. 35, no. 9, 2014, pp. 826-30.
Yu S, Dai M, Sun J, et al. [Comparison of clinical efficacy between HLA-mismatched related and HLA-matched unrelated donor hematopoietic stem cell transplantation for hematopoietic malignancies]. Zhonghua Xue Ye Xue Za Zhi. 2014;35(9):826-30.
Yu, S., Dai, M., Sun, J., Fan, Z., Huang, F., Zhang, Y., Jiang, Q., Zhou, H., Xu, D., Meng, F., & Liu, Q. (2014). [Comparison of clinical efficacy between HLA-mismatched related and HLA-matched unrelated donor hematopoietic stem cell transplantation for hematopoietic malignancies]. Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi, 35(9), 826-30. https://doi.org/10.3760/cma.j.issn.0253-2727.2014.09.009
Yu S, et al. [Comparison of Clinical Efficacy Between HLA-mismatched Related and HLA-matched Unrelated Donor Hematopoietic Stem Cell Transplantation for Hematopoietic Malignancies]. Zhonghua Xue Ye Xue Za Zhi. 2014;35(9):826-30. PubMed PMID: 25246252.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Comparison of clinical efficacy between HLA-mismatched related and HLA-matched unrelated donor hematopoietic stem cell transplantation for hematopoietic malignancies]. AU - Yu,Sijian, AU - Dai,Min, AU - Sun,Jing, AU - Fan,Zhiping, AU - Huang,Fen, AU - Zhang,Yu, AU - Jiang,Qianli, AU - Zhou,Hongsheng, AU - Xu,Dan, AU - Meng,Fanyi, AU - Liu,Qifa, PY - 2014/9/24/entrez PY - 2014/9/24/pubmed PY - 2015/5/20/medline SP - 826 EP - 30 JF - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi JO - Zhonghua Xue Ye Xue Za Zhi VL - 35 IS - 9 N2 - OBJECTIVE: To compare the clinical efficacy of HLA- mismatched related donor (MRD) and HLA-matched unrelated donor (MUD) hematopoietic stem cell transplantation (HSCT) for hematopoietic malignancies. METHODS: 174 patients with hematopoietic malignancies undergoing allogeneic HSCT (allo-HSCT) (82 from MRD and 92 from MUD) between June 2002 and December 2012 were enrolled in this retrospective study. Hematopoietic engraftment, graft versus host disease (GVHD), relapse, overall survival (OS) and disease-free survival (DFS) were compared between MRD and MUD group. RESULTS: There was no significant difference between MRD and MUD group in terms of age, gender, disease type and disease status before transplantation (all P>0.05). The incidence of Ⅰ-IV acute GVHD (aGVHD) was 62.2% and 54.3% in MRD and MUD group (P=0.295); the incidence of III-IV aGVHD between the two groups was 15.9% and 9.8% (P=0.229). The incidence of chronic GVHD (cGVHD) was 28.4% and 45.1% in MRD and MUD group (P=0.036), but there was no significant difference in the incidence of extensive cGVHD between the two groups (9.0% vs 12.2%, P=0.525). The mortality of GVHD was 8.5% and 10.9% in MRD and MUD group (P=0.605). The 10-year OS and DFS were (50.1±6.1)% and (48.8±6.1)% in MRD group, compared with (50.5±6.7)% and (46.3±6.2)% in MUD group (P=0.501, P=0.873, respectively). The 10-year cumulative relapse rate was (21.5±5.7)% and (37.6±7.3)% in MRD and MUD group (P=0.194). CONCLUSION: MRD is equivalent to MUD in efficacy and safety. Without HLA- matched related donors, MRD is superior to MUD because donor source is unlimited and transplantation could be made promptly according to disease status. SN - 0253-2727 UR - https://www.unboundmedicine.com/medline/citation/25246252/[Comparison_of_clinical_efficacy_between_HLA_mismatched_related_and_HLA_matched_unrelated_donor_hematopoietic_stem_cell_transplantation_for_hematopoietic_malignancies]_ L2 - http://journal.yiigle.com/LinkIn.do?linkin_type=pubmed&issn=0253-2727&year=2014&vol=35&issue=9&fpage=826 DB - PRIME DP - Unbound Medicine ER -